Shares ntawm Moderna Inc (NASDAQ: MRNA) tau nce ze li ntawm 25% rau hnub Tuesday tom qab lub tuam txhab biotech hais tias nws qhov kev sim tshuaj tiv thaiv melanoma pom tau tias muaj txiaj ntsig zoo hauv kev tshawb fawb me me.
Dab tsi ntxiv rau nws cov tshuaj tiv thaiv mRNA?
Thaum muab ua ke nrog Merck & Co Inc's (NYSE: MRK) Keytruda, nws cov tshuaj tiv thaiv mRNA tau ua pov thawj tias muaj txiaj ntsig zoo hauv kev txo qis kev mob qog noj ntshav ntawm daim tawv nqaij thiab tuag los ntawm qhov loj heev 44% piv rau kev kho nrog Keytruda nkaus xwb.
Puas yog koj tab tom nrhiav kom tau cov xov xwm ceev, kub-cov lus qhia thiab kev tsom xam kev ua lag luam?
Sau npe rau Invezz cov ntawv xov xwm, hnub no.
Moderna Tshuag kuj tseem nce ntxiv vim tias ob lub tuam txhab tam sim no npaj siab yuav pib qhov kev sim tshuaj thib 3 hauv xyoo 2023. Sib tham txog xov xwm tag kis no ntawm CNBC's "Squawk Box", Stephane Bancel - Tus Thawj Coj ntawm Moderna Inc tau hais tias:
Peb zoo siab vim qhov no yog qhov tseeb. Peb yuav tham nrog cov kws tswj xyuas kom pom tias peb tuaj yeem ua li cas txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm rau txhawm Yog li, nws yog ib hnub loj rau cov neeg mob.
Merck shares tseem tab tom ua lag luam me ntsis thaum sawv ntxov no.
Moderna khaws cia rau yav tom ntej possibilities
Moderna tseem yuav ua haujlwm nrog Merck kom pom tias kev sib xyaw ua ke ntawm nws cov tshuaj tiv thaiv mRNA thiab Keytruda tsuas yog siv tau rau lwm hom qog nqaij hlav, raws li cov ntaub ntawv. xovxwm tso tawm. CEO Bancel ntxiv:
Ua tsaug rau peb cov khoom, T-cell tuaj yeem paub ntau cov epitopes. Qhov ntawd yog qhov tseem ceeb [vim] raws li koj qhov mob qog noj ntshav hloov zuj zus, koj tuaj yeem khaws nws hauv kev kuaj xyuas, vim tias muaj 34 kev hloov pauv hauv txhua yam khoom rau cov neeg mob.
Lub hli tas los, Nasdaq-listed tuam txhab qhia cov txiaj ntsig nyiaj txiag rau nws lub quarter thib peb uas tuaj zoo hauv qab cov kws tshuaj ntsuam kev kwv yees.
Wall Street tam sim no pom zoo muas Moderna Tshuag uas yog nqis 13% rau lub xyoo ntawm kev sau ntawv.
Tau qhov twg los: https://invezz.com/news/2022/12/13/moderna-stock-up-25-on-mrna-cancer-vaccine/